Aktieanalys

2cureX Q4 2022: An efficient year - Redeye

{newsItem.title}

Redeye Publicerad: 23 Feb 2023 14:15

Redeye comments on 2cureX’s Q4’22 report. The company summarizes the past year and highlights its strong enrollment for the IGNITE program. Furthermore, 2cureX explains the processes of how new medical technologies become mainstream.

Länk till analysen i sin helhet: https://www.redeye.se/research/884078/2curex-q4-2022-an-efficient-year?utm_source=finwire&utm_medium=RSS

Nyheter om 2cureX

Läses av andra just nu

Om aktien 2cureX

Senaste nytt